Acyclovir for injection

This product is a synthetic nucleoside antiviral drug that has inhibitory effects on herpes simplex virus type I (HSV-1), type H (HSV-2) and varicella-zoster virus (VZV) both in vivo and in vitro. Cell culture results show that this product has the strongest inhibitory effect on HSV-1 virus, followed by HSV-2 and VZV viruses. Because this product has affinity for thymidine kinase (TK) encoded by HSV and VZV, it has a highly selective inhibitory effect. This type of viral enzyme converts acyclovir into acyclovir monophosphate, a nucleoside analog. The monophosphate is further converted into diphosphate by guanylate kinase in the cell, and then converted into triphosphate by multiple enzymes in the cell. In vitro, acyclovir triphosphate stops herpes virus DNA replication.

The main ingredient of this product is acyclovir, and its chemical name is: 9-[(2-hydroxyethoxy)methyl]guanine

This product is a colorless clear liquid.

This product is used for 1. Herpes simplex virus infection: for the treatment of primary and recurrent mucocutaneous infections in immunocompromised individuals and the prevention of recurrent cases; also for the treatment of herpes simplex encephalitis. 2. Herpes zoster: for the treatment of severe herpes zoster in immunocompromised individuals or diffuse herpes zoster in immunocompetent individuals. 3. The treatment of varicella in immunocompromised individuals.

For intravenous infusion only, and each infusion time is more than 1 hour. Common adult dosage: 1. For the initial treatment of severe genital herpes, 5 mg/kg (calculated as acyclovir, the same below) per body weight, 3 times a day, drip every 8 hours, for 5 days. 2. For immunocompromised patients with skin and mucous membrane herpes simplex or severe herpes zoster, 5-10 mg/kg per body weight, 3 times a day, drip every 8 hours, for 7-10 days. 3. For herpes simplex encephalitis, 10 mg/kg per body weight, 3 times a day, drip every 8 hours, for 10 days. The maximum daily dose for adults is 30 mg/kg per body weight, or 1.5 g/m2 per body surface area.

1 Common adverse reactions: Inflammation or phlebitis at the injection site, itching or urticaria, rash, fever, mild headache, nausea, vomiting, diarrhea, proteinuria, increased blood urea nitrogen and serum creatinine, abnormal liver function such as mild increase in serum aminotransferase, alkaline phosphatase, lactate dehydrogenase, and total bilirubin. 2 Rare adverse reactions include: acute renal insufficiency, decreased white blood cells and red blood cells, decreased hemoglobin, neutropenia, thrombocytopenic purpura, increased cholesterol and triglycerides, hematuria, hypotension, sweating, palpitations, dyspnea, and chest tightness. 3 Adverse reactions observed in clinical practice after the product was marketed include: (1) Digestive system:

It is contraindicated in patients who are allergic to acyclovir.

1. When used in combination with interferon or methotrexate (intrathecal), it may cause mental abnormalities and should be used with caution. 2. When used in combination with nephrotoxic drugs, it can aggravate nephrotoxicity, especially in patients with renal insufficiency. 3. When used in combination with zidovudine, it can cause nephrotoxicity, manifested as severe lethargy and fatigue. 4. It competitively inhibits the secretion of organic acids with probenecid. When used in combination with probenecid, it can slow down the excretion of this product, prolong its half-life, and cause drug accumulation in the body.

Sealed and stored in a cool place.

0.25g

Hubei Hepu Pharmaceutical Co., Ltd.

• Founded in:

  2002-01-09

• Address:

  No. 2, South Fourth Street, Jinyin Lake, Dongxihu District, Wuhan

• Tax NO.:

  91420000732738617L

• Registered Funds:

  20 million yuan

• Website:

  Log in to view

• Email:

  Log in to view